CPH signs Brazilian commercial agreement for distribution of cannabinoid-derived nutraceutical products
Creso Pharma Limited (ASX:CPH) has signed a binding Letter of Intent (LOI) with Brazil-based market-access and distribution service company Sin Solution, giving the leading supplier of cannabinoid-derived products a strategic foothold in the vast Latin American market.
As part of the agreement, Sin Solution will assist Creso with the commercialisation of its premium Swiss Vitamin nutraceuticals and its cannabinoid-derived nutraceutical products in Brazil – with sales targeting the privately insured middle class population of 60 million people with a potential market worth over $US800 million.
However, the take up of this product in Brazil remains to be seen. Investors considering this stock for their portfolio, should seek professional financial advice.
Sin Solution works with a number of high-profile commercial partners in Brazil and beyond, including giant Johnson & Johnson as well as GSK, Danone and Ache Do Brasil.
Through Sin Solution, CPH will be working with the following key marketing and distribution partners:
- Medicinal prescription and over-the-counter (OTC) pharmaceuticals and distribution company, Ache Do Brasil, who has more than 65,000 points of sales in Brazil. It promotes 316 brands and had 2015 net revenues of R$2.3 billion (AU$1 billion);
- Hypermarcas, the number one OTC pharmaceuticals company in Brazil has 15% market share and sales totalling R$1 billion (AU$420 million) in 2015, and;
- Biolab – among the top-10 biggest pharmaceutical companies in Brazil, with a field force of 1050 people. Biolab had sales of US$370 million in 2015, covering 250,000 medical professionals in Brazil and a market share of 2.13%.
In addition Sin Solution has direct access to more than 350,000 health professionals and over 200,000 direct patients.
The LatAm market is key for Creso Pharma, and consequently the ability to make a strong start in Brazil will put the company in prime position to launch its products in surrounding countries.
Sin Solution will act as a commercial partner for the commercialisation of Creso’s various Swiss Vitamin premium nutraceutical products as well as its cannabinoid-derived nutraceutical products.
The Swiss Vitamin premium nutraceutical products are based on INNutri’s unique delivery technology – with buccal absorption and high bioavailability – of premium vitamin mixes which can be used to support a variety of health needs. The range is targeted at the active middle-class working population.
This is the first step on a journey that will eventually see Creso launch its cannabinoid-derived nutraceutical products, which use the same innovative buccal delivery technology, to treat anxiety and stress.
As part of the process, Creso will register the premium Swiss Vitamin products in Brazil, followed by a launch in the second half of 2018 and the first sales of its products in the country.
“This agreement gives Creso entry into Latin America via a strategic partner in the continent’s largest economy, Brazil,” said Creso Pharma Group CEO and Co-Founder, Dr. Miri Halperin Wernli.
“Working with Sin Solution gives us access to further key commercial partners in the region and allows us to tap into a vast and fast-growing market, supporting the long-term growth of our business.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.